Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Zoetis Inc. (NYSE:ZTS)

Posted by Stanley Muller on May 12th, 2026

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on April 14th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 5/1/2026.
Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 5/1/2026.
Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 5/1/2026.
Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 5/1/2026.
Sold $1,001 – $15,000 in shares of SS&C Technologies (NASDAQ:SSNC) on 5/1/2026.
Purchased $1,001 – $15,000 in shares of Wayfair (NYSE:W) on 5/1/2026.
Purchased $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 5/1/2026.
Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 5/1/2026.
Purchased $1,001 – $15,000 in shares of Sensata Technologies (NYSE:ST) on 5/1/2026.
Purchased $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 5/1/2026.

Zoetis Stock Up 0.3%

ZTS stock traded up $0.25 during trading on Tuesday, reaching $76.92. The stock had a trading volume of 18,424,772 shares, compared to its average volume of 4,881,687. Zoetis Inc. has a 1-year low of $75.11 and a 1-year high of $172.23. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The company has a market capitalization of $32.25 billion, a P/E ratio of 12.76, a PEG ratio of 1.29 and a beta of 0.87. The firm has a fifty day moving average price of $116.50 and a 200 day moving average price of $122.77.

Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the firm earned $1.48 EPS. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.96 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ZTS. Global Wealth Strategies & Associates acquired a new position in Zoetis in the 4th quarter valued at approximately $25,000. Prosperity Bancshares Inc acquired a new position in Zoetis in the 4th quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis in the 3rd quarter valued at approximately $31,000. Cassaday & Co Wealth Management LLC acquired a new position in Zoetis in the 1st quarter valued at approximately $28,000. Finally, Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the 4th quarter worth $30,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZTS has been the subject of several research analyst reports. Piper Sandler reissued a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. UBS Group dropped their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday. Citigroup initiated coverage on shares of Zoetis in a research report on Wednesday, April 15th. They issued a “buy” rating and a $145.00 target price for the company. Stifel Nicolaus set a $105.00 target price on shares of Zoetis in a research report on Friday. Finally, Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $141.25.

View Our Latest Stock Report on ZTS

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Zoetis Company Profile

(Get Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.